Furthermore, in the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes, it is strongly recommended that SGLT-2 inhibitors be the first-choice antihyperglycemic therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease (ASCVD) [18]. Here, SLC5A2 is linked to cardiovascular disorder.